|Day Low/High||3.80 / 3.87|
|52 Wk Low/High||3.24 / 13.80|
CEO Zami Aberman to Present at BIO KOREA 2014 on May 29
CEO Zami Aberman to Present Case Study on Placenta-Based Cell Therapies and Participate in Panel on Cell Therapy Funding and Deal Making
Pluristem to Comprise 2% of the Index Scheduled to Launch on May 11, 2014
Company Can Expand Into, and Advance Its Clinical Trials, in Any European Union Member Nation
Key Meetings With Congress and the FDA With a Goal Towards More Rapidly Bringing Breakthrough Cell Therapies to Market
Pluristem's Dr. Ohad Karnieli Confirmed as Chair of ISCT's Influential Process and Product Committee for a 2-Year Post
Independent Study Shows Use of PLX-PAD Human Placental-Derived Adherent Stromal Cells Improves Tendon Healing in a Preclinical Model of Tendon Injury
Aberman to Discuss Collaborative Models and Partnerships That Enable Successful Commercialization of Gene and Cell Therapies
Pluristem Fortifies Leadership Position in Cell Therapy Following Multiple Regulatory Approvals of Its New PLX Cell Mass Production Facility
Orphan Drug Designation May Provide Benefits Including 7 Year Market Exclusivity, Tax Credits, and FDA's Guidance on Clinical Studies
Covers Commercial Rights for 3D Manufacturing Methods and Composition of Matter for Placental or Fat Cells
Panel: Disrupting the Pharma Model With Allogeneic Stem Cell Therapies
PLX-PAD Cells Offer Promising Potential Treatment for Preeclampsia; Currently no Treatment Exists Other Than Early Delivery
NIAID's Next Study of PLX-RAD Cells to be Initiated in February
Pluristem's successful stem cell trial last week on muscle injuries is an important first step for the company, says the company's CEO Zami Aberman.
Aberman to Share Pluristem's Expertise in Cell Therapies at Four Sessions During the Three Day Conference
Investors in Pluristem Therapeutics Inc saw new options begin trading this week, for the September 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
First of Many Expected Regulatory Approvals for the New Facility Strengthens Pluristem's Leadership Position in Commercial-Scale Cell Manufacturing Technologies
PLX-PAD Cells Show Statistically Significant Improvement Over Placebo in the Change of the Maximal Contraction Force of the Gluteal Muscle
Broad Patent Addresses Several Pluristem Indications in Clinical Development
Principal Investigator of the Study Will Join Pluristem Management to Announce Results at the Tel Aviv Stock Exchange
CHA Bio Will Conduct and Fund the Trial; PLX-PAD Cells Are the First Placental-Derived Allogeneic Cells Approved for Importation Into South Korea
Important Milestone Advances Pluristem's Clinical Development Program for the Treatment of Preeclampsia Using PLX-PAD Cells
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.